This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

The head and neck district represents one of the most frequent sites of cancer, and the
percentage of metastases is very high in both loco-regional and distant areas. Prognosis …

Background Targeting the programmed cell death protein 1 (PD-1)/programmed cell death
ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and …

Radiotherapy is one of the most common treatments for oral cancer. However, in the clinic,
recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying …

Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …

Background: Pre-treatment weight loss (WL) is a prognostic indicator for overall survival
(OS) in head and neck cancer (HNC) patients. This study investigates the association …

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in
Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial …

Despite the rising incidence of human papillomavirus related (HPV+) oropharyngeal
squamous cell carcinoma (OPSCC), treatment of metastatic disease remains palliative. Even …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With
Recurrent or Metastatic Head and Neck Cancer - PMC Back to Top Skip to main content NIH …

Despite substantial improvements in head and neck squamous cell carcinoma (HNSCC)
treatment, the major obstacle to long‐term survival remains disease recurrence. Salvage …